CRYSVITA (burosumab) recall in Canada: Risk of severe hypercalcemia
In plain language
This recall involves CRYSVITA (burosumab) solution for injection sold in Canada. It's being recalled because it may increase the risk of severe hypercalcemia (high calcium levels in the blood). Patients should discuss any concerns with their healthcare professional.
What to do
- Discuss any questions or concerns about this information with your healthcare professional.
- Inform your healthcare professional if you are experiencing any side effects while receiving CRYSVITA.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
CRYSVITA (burosumab), solution for subcutaneous injection
Why this matters
Risk of severe hypercalcemia
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of severe hypercalcemia
What should consumers do?
Discuss any questions or concerns about this information with your healthcare professional. Inform your healthcare professional if you are experiencing any side effects while receiving CRYSVITA.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of severe hypercalcemia
When was this product recalled?
This product was recalled on August 25, 2025.
Is the CRYSVITA brand affected by this recall?
Yes, CRYSVITA products are affected by this recall. This recall involves CRYSVITA (burosumab) solution for injection sold in Canada. It's being recalled because it may increase the risk of severe hypercalcemia (high calcium levels in the blood). Patients should discuss any concerns with their healthcare professional.